New regulations bring new risks to life sciences firms

The pharmaceutical and life sciences industry is among the most heavily regulated in the world. Today, these companies face unprecedented compliance challenges, and the close regulatory scrutiny to which they are subject is unlikely to abate anytime soon.

Implementing an aggregate spend program in a global marketplace
Learn more.
HRI regulatory center
Learn more.
PwC scores top rating in Risk and Compliance Consulting.
Learn more
1 2 3

Compliance as a market differentiator for pharma companies

At no time have risk resilience and the need to effectively manage compliance been more important to the pharmaceutical and life sciences industry. Companies have to consider a wide range of emerging risks as they adapt their business to changing regulatory and market-driven pressures, including globalization, the advancement of technology, and the changing expectations of stakeholders. New information systems, strategies and processes to manage compliance are rapidly evolving in response to these pressures. Companies are increasingly realizing the value of investments in regulatory compliance by developing approaches that leverage compliance for business growth and increasing competitive differentiation.


Aligning risk and compliance plans for cost efficiencies

Understanding the importance of properly diagnosing risks, and ensuring the proper controls to address compliance issues.

Learn more.


Pharma aggregate spend benchmarking results

Life sciences companies have been developing aggregate spend programs with a focus on US State and Federal reporting. Our January 2014 webcast talks about how this will impact the industry.

Learn more.